Dalibor Sames

This inventor holds 16 USPTO granted patents and 15 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Opioid Receptor Modulators. Top assignees: Columbia University, Sloan-Kettering Institute for Cancer Research, Research Foundation for Mental Hygiene, Inc.. Active years: 2003-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dalibor Sames. Retrieved from https://idiyas.com/inventor/dalibor-sames

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 15)

% Patents Active = 81.3

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 2 (Patent Applications = 12)

Average Co-Inventor Count = 4.6

ph-index = 6

Forward Citations = 98(Granted Patents)

Company Filing History:

Sloan-Kettering Institute for Cancer Research

patents

1 out of 45

Research Foundation for Mental Hygiene, Inc.

patents

4. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2026

Loading Chart...

Areas of Expertise:

Ibogaine Analogs

Opioid Receptor Modulators

Mitragynine Alkaloids

GDNF Inducers

Neuropsychiatric Disorders

Fluorescent Neurotransmitters

Mu-Opioid Agonists

Carboxylic Diarythiazepineamines

Pain Treatment

Mood Disorders

Substance Use Disorders

Toxicity Reduction

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12564597 - Ibogaine analogs as therapeutics for neurological and psychiatric disorders (2026-03-03),

2. 12195478 - Opioid receptor modulators (2025-01-14),

3. 11912707 - Mitragynine alkaloids as opioid receptor modulators (2024-02-27),

4. 11840541 - Opioid receptor modulators (2023-12-12),

5. 11787772 - Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists (2023-10-17),

6. 11760758 - Mitragynine analogs for the treatment of pain, mood disorders and substance use disorders (2023-09-19),

7. 10961244 - Mitragynine alkaloids as opioid receptor modulators (2021-03-30),

8. 10844027 - Carboxylic diarylthiazepineamines as mu-opioid receptor agonists (2020-11-24),

9. 10183919 - Class of mu-opioid receptor agonists (2019-01-22),

10. 9988377 - Small molecule inducers of GDNF as potential new therapeutics for neuropsychiatric disorders (2018-06-05),

11. 9075014 - pH-responsive fluorescent false neurotransmitters and their use (2015-07-07),

12. 8859615 - Compounds, compositions and methods for reducing toxicity and treating or preventing diseases (2014-10-14),

13. 8337941 - Fluorescent substrates for monoamine transporters as optical false neurotransmitters (2012-12-25),

14. 7550146 - Glycopeptide conjugates and uses thereof (2009-06-23),

15. 7160856 - α-O-linked glycoconjugates, methods of preparation and uses thereof (2007-01-09),

Title: Dalibor Sames: Innovator in Opioid Receptor Modulation

Introduction

Dalibor Sames is a prominent inventor based in New York, NY, known for his significant contributions to the field of opioid receptor modulation. With a total of 15 patents to his name, Sames has made remarkable strides in developing compounds that address various medical conditions.

Latest Patents

Among his latest patents, Sames has developed compounds that serve as opioid receptor modulators. These inventions include a compound with a specific structure that incorporates various ring structures and substituents. Additionally, he has worked on mitragynine alkaloids as opioid receptor modulators, providing methods for treating pain, depressive disorders, mood disorders, and anxiety disorders through the administration of these compounds.

Career Highlights

Dalibor Sames has had a distinguished career, working with esteemed institutions such as Columbia University and the Sloan Kettering Institute for Cancer Research. His work has significantly impacted the understanding and treatment of pain and related disorders.

Collaborations

Sames has collaborated with notable colleagues, including Andrew Carry Kruegel and Jonathan A. Javitch, further enhancing the scope and impact of his research.

Conclusion

Dalibor Sames continues to be a leading figure in the field of opioid receptor modulation, with his innovative patents paving the way for advancements in medical treatments. His contributions are vital in addressing complex health issues related to pain and mood disorders.

Profile summary based on public USPTO records.